Gilead Sciences Couldn’t Have Timed its Splash Into CAR-T Better – Motley Fool
|
Gilead Sciences Couldn’t Have Timed its Splash Into CAR–T Better
Motley Fool The FDA approved the world’s first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion. …. and reengineer them in a certain … |
|
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR–T Therapy Axicabtagene Ciloleucel
PR Newswire (press release) Jerrell Shelton, CEO of Cryoport, stated, “Kite’s CAR T-cell therapy for non-Hodgkin lymphoma is based on pioneering science which uses the patients’ own immune cells to treat cancers. It offers hope to patients who previously had no other option left … |
|
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR–T Therapy Axicabtagene Ciloleucel
Markets Insider Jerrell Shelton, CEO of Cryoport, stated, “Kite’s CAR T-cell therapy for non-Hodgkin lymphoma is based on pioneering science which uses the patients’ own immune cells to treat cancers. It offers hope to patients who previously had no other option left … Gilead Sciences Couldn’t Have Timed its Splash Into CAR–T BetterMotley Fool |
Madison.com |
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Madison.com The Kite Pharma deal comes ahead of an expected FDA decision on its CAR–T, axi-cel, on Nov. 29. It’s not a given that axi-cel will get a green light, but it delivered a better than 50% complete response rate in trials, and the FDA opted against holding … |